<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Recognizing EGFR as key orchestrator of the metastatic process in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, but also the substantial <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> of responses to anti-EGFR therapy, we examined the pattern of composite <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> kinase activities governed by EGFR-mediated signaling that might be implicated in development of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: Point mutations in KRAS, BRAF, and PIK3CA and ERBB2 amplification were determined in <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> from 63 patients with locally advanced <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> scheduled for radical treatment </plain></SENT>
<SENT sid="2" pm="."><plain>Using <z:chebi fb="7" ids="16670">peptide</z:chebi> arrays with tyrosine kinase substrates, ex vivo phosphopeptide profiles were generated from the same baseline <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> samples and correlated to <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e>-free survival </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Unsupervised clustering analysis of the resulting phosphorylation of 102 array substrates defined two <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> classes, both consisting of cases with and without KRAS/BRAF mutations </plain></SENT>
<SENT sid="4" pm="."><plain>The smaller cluster group of patients, with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> generating high ex vivo phosphorylation of phosphatidylinositol-3-kinase-related substrates, had a particularly <z:e sem="disease" ids="C0001807" disease_type="Mental or Behavioral Dysfunction" abbrv="">aggressive disease</z:e> course, with almost a half of patients developing <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e> within one year of follow-up </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSION: High phosphatidylinositol-3-kinase-mediated signaling activity of the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e>, rather than KRAS/BRAF mutation status, was identified as a hallmark of poor <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e>-free survival in patients with locally advanced <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> undergoing radical treatment of the pelvic cavity </plain></SENT>
</text></document>